These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 24467968)

  • 1. Biologic therapies in inflammatory bowel disease.
    Cohen LB; Nanau RM; Delzor F; Neuman MG
    Transl Res; 2014 Jun; 163(6):533-56. PubMed ID: 24467968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of biologics and the role of therapeutic monitoring.
    Lin K; Mahadevan U
    Gastroenterol Clin North Am; 2014 Sep; 43(3):565-79. PubMed ID: 25110259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel targets for inflammatory bowel disease therapeutics.
    Löwenberg M; D'Haens G
    Curr Gastroenterol Rep; 2013 Feb; 15(2):311. PubMed ID: 23314806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in inflammatory bowel disease.
    Ahluwalia JP
    Med Clin North Am; 2012 May; 96(3):525-44, x. PubMed ID: 22703854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crohn's targeted therapy: myth or real goal?
    Schmidt KJ; Büning J; Jankowiak C; Lehnert H; Fellermann K
    Curr Drug Discov Technol; 2009 Dec; 6(4):290-8. PubMed ID: 20025597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Safety and effectiveness of biologics in treating inflammatory bowel diseases in pregnancy].
    Tursi A
    Recenti Prog Med; 2010 Oct; 101(10):396-401. PubMed ID: 21137576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel biologics in inflammatory bowel disease.
    Papachristou GI; Plevy S
    Gastroenterol Clin North Am; 2004 Jun; 33(2):251-69, ix. PubMed ID: 15177537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of biologic agents in pregnancy and breastfeeding.
    Horst S; Kane S
    Gastroenterol Clin North Am; 2014 Sep; 43(3):495-508. PubMed ID: 25110255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positioning biologic therapy for Crohn's disease and ulcerative colitis.
    Velayos FS; Sandborn WJ
    Curr Gastroenterol Rep; 2007 Dec; 9(6):521-7. PubMed ID: 18377806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current status of new drug development for inflammatory bowel diseases].
    Kohgo Y; Tanabe H; Fujiya M
    Nihon Rinsho; 2012 Feb; 70 Suppl 1():378-82. PubMed ID: 23126121
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis.
    Singh S; Garg SK; Pardi DS; Wang Z; Murad MH; Loftus EV
    Mayo Clin Proc; 2014 Dec; 89(12):1621-35. PubMed ID: 25441399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic therapy for inflammatory bowel disease.
    Ardizzone S; Bianchi Porro G
    Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
    Ben-Horin S; Novack L; Mao R; Guo J; Zhao Y; Sergienko R; Zhang J; Kobayashi T; Hibi T; Chowers Y; Peyrin-Biroulet L; Colombel JF; Kaplan GG; Chen MH
    Gastroenterology; 2022 Feb; 162(2):482-494. PubMed ID: 34757139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent developments in the treatment of inflammatory bowel disease.
    Rietdijk ST; D'Haens GR
    J Dig Dis; 2013 Jun; 14(6):282-7. PubMed ID: 23419117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
    Molnár T
    Orv Hetil; 2009 Sep; 150(38):1773-9. PubMed ID: 19740722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biologic therapies in chronic inflammatory bowel diseases].
    Reenaers C; Louis E; Belaiche J
    Rev Med Liege; 2009; 64(5-6):301-4. PubMed ID: 19642463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease.
    Chang JT; Lichtenstein GR
    Nat Clin Pract Gastroenterol Hepatol; 2006 Apr; 3(4):220-8. PubMed ID: 16582964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.